Key Insights• According to the research report, "Russia EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Russia EPA & DHA Market is anticipated to grow at more than 5.52% CAGR from 2026 to 2031. The Russian EPA & DHA market is steadily expanding as the country faces a high burden of cardiovascular disease, demographic decline, and rapidly growing consumer use of dietary supplements (biologically active additives, or BAA), which has made omega-3 one of the most visible product categories in Russian pharmacies and online marketplaces. Russia's population is estimated at approximately 146 million, and the country is experiencing a pronounced demographic contraction, with around 1.22 million births recorded in 2024, the lowest annual level since 1999. In 2025, Rosstat restricted the routine publication of detailed monthly demographic statistics. Diseases of the circulatory system remain the leading cause of death in Russia, although Health Minister Mikhail Murashko reported at the Russian National Congress of Cardiologists in September 2025 that cardiovascular mortality had fallen by 34% since 2000. The persistent clinical burden is placing additional pressure on Russia's healthcare system and consumer health sector to strengthen access to EPA and DHA through supplements, medicines, fortified foods, and infant nutrition.• Russia's EPA & DHA market is characterized by a large and rapidly formalizing dietary supplement ecosystem comprising domestic manufacturers, pharmacy chains, online marketplaces, and a reduced but still significant presence of international brands. According to the Center for Development of Advanced Technologies (CRPT), operator of the national Chestny Znak labelling system, Russia's legal dietary supplement market reached RUB 279 billion in 2025, equivalent to 894 million packages, with pharmacies accounting for RUB 224 billion and online channels for RUB 55 billion.

Domestic manufacturers such as Evalar, Mirrolla, and Biafishenol, alongside contract manufacturers and private-label producers for marketplaces such as Ozon and Wildberries, have expanded their share following the partial withdrawal of Western brands since 2022. Russia also has domestic fish oil raw material supply from Far Eastern pollock, cod, and salmon fisheries, supporting local production of cod liver oil and fish oil.• Regulatory oversight for EPA and DHA products is administered by the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) under the technical regulations of the Eurasian Economic Union (EAEU), including TR CU 021/2011 on food safety and TR CU 022/2011 on food labelling. Dietary supplements require state registration and a certificate of state registration before marketing, while omega-3 medicines are registered by the Ministry of Health. Mandatory digital labelling of dietary supplements through the Chestny Znak system was introduced in two stages in 2023 and 2025. Federal Law No. 150-FZ, adopted in 2025 and effective from September 1, 2025, strengthened state regulation of the supplement market, including government authority to set quality criteria for supplements and raw materials, restrictions on interactions between medical workers and supplement manufacturers, and pre-trial blocking of websites selling unlabeled supplements.Market Outlook• A defining characteristic of Russia's EPA & DHA market is the rapid tightening of quality control and market surveillance. In 2025, Roskachestvo tested omega-3 capsules from 15 brands and found that 60% of samples failed mandatory requirements, with 40% showing omega-3 content violations, 27% EPA content violations, 53% DHA content violations, and 13% registration or labelling issues.

The results have increased consumer and regulatory focus on verified EPA and DHA content, encouraging consolidation toward manufacturers with robust quality systems. At the same time, CRPT reports that violations detected through the labelling system fell by 45% compared with the previous year, indicating improving compliance. From October 2026, Roszdravnadzor is set to monitor doctors' prescriptions of dietary supplements, under a framework in which the Ministry of Health and Rospotrebnadzor will determine which supplements may be recommended for specific conditions.• The market also reflects Russia's growing emphasis on cardiovascular prevention and the national demographic agenda. The national project framework on long and active life prioritizes reducing cardiovascular mortality, and cardiologists increasingly discuss omega-3 within lipid management and secondary prevention. The integration of supplement prescriptions into medical practice under Law No. 150-FZ is expected to formalize the role of evidence-based omega-3 products recommended by physicians. In infant nutrition, the decline in births to approximately 1.22 million in 2024 is constraining infant formula volumes, although government support for families and maternity is encouraging premium DHA-fortified formula and prenatal supplement demand.Market DynamicsDriver: High cardiovascular disease burden and rapid growth of the formalized supplement marketRussia's EPA & DHA market is primarily driven by the high prevalence of cardiovascular disease and the rapid expansion of supplement consumption.

Diseases of the circulatory system remain the leading cause of death in Russia, and cardiovascular risk factors such as hypertension, dyslipidemia, obesity, and smoking are widespread. Consumer interest in preventive health has fueled strong growth of the dietary supplement market, which reached RUB 279 billion in 2025 according to CRPT, with omega-3 among the most purchased categories in pharmacies and on online marketplaces. Low consumption of oily fish in many inland regions creates a structural dietary gap in EPA and DHA. As physicians gain a formal role in recommending supplements under Law No. 150-FZ, pharmacies and marketplaces are witnessing sustained demand for EPA and DHA products with verified content and quality.Challenge: Product quality concerns, sanctions-related supply disruption, and demographic declineOne of the principal challenges facing Russia's EPA & DHA market is the inconsistent quality of omega-3 products, highlighted by Roskachestvo's 2025 testing in which 60% of omega-3 samples failed mandatory requirements. Inaccurate EPA and DHA content undermines consumer trust and creates reputational risk for the category. Additionally, sanctions and logistical disruptions since 2022 have complicated imports of refined fish oil, high-concentration oils, krill oil, and algal oil from Western suppliers, increasing reliance on domestic production and imports from China and other friendly jurisdictions.

Global raw material volatility also affects pricing, with Peru's first 2026 north-central anchovy quota set approximately 36% lower than in 2025. The demographic decline, with births at their lowest level since 1999, is reducing the addressable market for infant formula. Together, these factors contribute to quality risk, supply chain complexity, and pricing pressure.Trend: Import substitution, domestic production, and growth of marketplace-driven omega-3 salesRussia is experiencing a significant shift toward domestic production and digital distribution of omega-3 products. Domestic manufacturers are expanding fish oil and omega-3 concentrate production using Far Eastern marine raw materials, while contract manufacturers produce private-label omega-3 products for marketplaces such as Ozon and Wildberries, which have become key channels for supplement sales. Online channels accounted for RUB 55 billion of supplement sales in 2025, according to CRPT. Simultaneously, imports of algal DHA and refined oils from China are increasing as supply chains reorient.

The mandatory Chestny Znak labelling system is improving traceability and enabling consumers to verify product authenticity, while the planned monitoring of supplement prescriptions from October 2026 is expected to support evidence-based, physician-recommended omega-3 products. The growing emphasis on children's health and prenatal nutrition is also boosting demand for DHA-rich products.Policies• EAEU Technical Regulations and State Registration: Dietary supplements containing EPA and DHA are regulated under EAEU technical regulations, including TR CU 021/2011 on food safety and TR CU 022/2011 on food labelling. Products must undergo state registration with Rospotrebnadzor and obtain a certificate of state registration before marketing, with requirements for composition, safety, and labelling.• Mandatory Digital Labelling (Chestny Znak): Dietary supplements are subject to mandatory digital labelling through the national Chestny Znak system, introduced in two stages in 2023 and 2025, enabling traceability from production to sale and supporting enforcement against counterfeit and unregistered products.• Federal Law No. 150-FZ on Dietary Supplements: Effective September 1, 2025, Law No. 150-FZ allows the government to set quality criteria for supplements and raw materials, prohibits medical workers from accepting payments, gifts, or samples from supplement manufacturers, restricts the use of certain raw materials, and introduces pre-trial blocking of websites selling unlabeled supplements prohibited for sale.• Supplement Prescription Framework: Under the 2025 legal framework, the Ministry of Health and Rospotrebnadzor will determine which supplements may be prescribed by doctors and for which conditions, with Roszdravnadzor set to monitor supplement prescriptions from October 2026.• Medicine Registration and Quality Testing: Omega-3 medicines must be registered by the Ministry of Health under the Federal Law on the Circulation of Medicines and EAEU rules, while Roskachestvo conducts independent quality testing of consumer products, including omega-3 supplements, publishing results that influence consumer choice and regulatory attention.Segment AnalysisRussia EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Russia, particularly in children's supplements, prenatal products, and infant formula. Roskachestvo's 2025 testing found DHA content violations in 53% of tested omega-3 samples, highlighting the importance of verified DHA content.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Russia, driven by increasing physician interest in high-EPA concentrates and omega-3 medicines for triglyceride management and cardiovascular prevention.Russia EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Russia due to its cost-effectiveness, domestic raw material availability from Far Eastern fisheries, and broad consumer familiarity, including traditional cod liver oil products.• Algae Oil maintains a growing position within Russia, particularly in infant formula and children's products, with supply increasingly sourced from Chinese algal oil producers.• Krill Oil is a premium source category with limited availability following disruptions to Western supply chains, sold mainly through pharmacies and marketplaces.• Other Marine Sources hold a niche position in the Russian market, including salmon oil, seal oil, and marine phospholipids, primarily used in specialty supplements and pet nutrition.Russia EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Russia, within a legal supplement market of RUB 279 billion in 2025, distributed primarily through pharmacies and online marketplaces.• Pharmaceuticals represent an important application segment, including registered omega-3 medicines for hypertriglyceridemia and cardiovascular prevention distributed through pharmacies and hospitals.• Infant Formula represents a strategically important application segment, with DHA widely included in formulas, although births of approximately 1.22 million in 2024 are constraining volumes.• Food & Beverages encompasses omega-3-enriched dairy, eggs, and functional foods, as well as canned fish products, regulated under EAEU technical regulations.• Clinical Nutrition & Medical Foods includes fish oil-based lipid emulsions for parenteral nutrition and enteral formulas used in hospitals.• Pet Nutrition represents the fastest-growing application segment in Russia, supported by high pet ownership, the localization of pet food production, and growing demand for premium foods and supplements incorporating fish oil.Major EPA & DHA Manufacturers Operating in Russia• Evalar, Mirrolla, Biafishenol, Abbott, Nestlé, Danone (Nutricia), Infaprim, and a range of contract manufacturers and private-label producers for online marketplaces are leading players in the Russian EPA & DHA market, offering fish oil and omega-3 supplements, omega-3 medicines, and DHA-fortified infant formula. Their strong presence, pharmacy and marketplace distribution, and growing domestic production capacity have driven adoption across the Russian market.• The market is also supported by domestic fish processors, ingredient importers sourcing from China and other partner countries, and testing organizations such as Roskachestvo that provide quality oversight. With a rapidly formalizing supplement market and import substitution policies, Russia is increasingly reliant on domestic and Asian omega-3 supply chains.Russia EPA & DHA Supply and Pricing Economics• EPA and DHA products in Russia represent value-added nutritional products whose pricing depends on source, concentration, brand positioning, labelling compliance costs, and import logistics.

Pricing varies considerably between domestic fish oil, imported concentrates, and algal oil.• Retail pricing is influenced by the ruble exchange rate, sanctions-related logistics costs, and global raw material prices. The reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on imported refined oil prices.• Supplements are paid out-of-pocket, while omega-3 medicines may be partially covered through regional drug provision programs for eligible patients.• Compliance with the Chestny Znak labelling system and Law No. 150-FZ adds operational costs, favoring larger domestic manufacturers with integrated quality systems.Market Outlook by Consumer Health Spending and Supply Infrastructure• Russia's EPA & DHA market growth is strongly linked to consumer health spending, the formalization of the supplement sector, and the expansion of pharmacy and marketplace channels, although product quality concerns, sanctions-related supply disruption, and demographic decline remain significant factors influencing development.• Private consumer spending drives the supplement segment, while the integration of supplement prescriptions into medical practice is expected to strengthen physician-led demand for omega-3 products from October 2026.• The future growth opportunity for EPA and DHA in Russia depends on improving product quality and verified EPA and DHA content, expanding domestic omega-3 production, securing stable import supply from partner countries, and strengthening evidence-based cardiovascular prevention. Greater use of traceability through the Chestny Znak system and quality testing will likely become key strategies for restoring consumer trust and supporting long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.